UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer

Nature reviews. Urology, 2021-12, Vol.18 (12), p.739-762

2021

Volltextzugriff (PDF)

The Use of Soy Isoflavones in the Treatment of Prostate Cancer: A Focus on the Cellular Effects

Nutrients, 2023-11, Vol.15 (23), p.4856

2023

Volltextzugriff (PDF)

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial

BMC cancer, 2021-10, Vol.21 (1), p.1113-1113, Article 1113

2021

Volltextzugriff (PDF)

Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer

EJNMMI research, 2021-04, Vol.11 (1), p.41-10, Article 41

2021

Volltextzugriff (PDF)

SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?

BMC cancer, 2022-12, Vol.22 (1), p.1294-1294, Article 1294

2022

Volltextzugriff (PDF)

Defining the optimal template of salvage lymph node dissection for unilateral pelvic nodal recurrence of prostate cancer following radical prostatectomy

International journal of urology, 2023-01, Vol.30 (1), p.92-99

2023

Volltextzugriff (PDF)

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial

BMC cancer, 2020-05, Vol.20 (1), p.457-7, Article 457

2020

Volltextzugriff (PDF)

Metastasectomy for visceral and skeletal oligorecurrent prostate cancer

World journal of urology, 2019-08, Vol.37 (8), p.1543-1549

2019

Volltextzugriff (PDF)

Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT: impact of postoperative treatments

World journal of urology, 2021-02, Vol.39 (2), p.399-406

2021

Volltextzugriff (PDF)

Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy

Cancers, 2020-08, Vol.12 (8), p.2271

2020

Volltextzugriff (PDF)

Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study

Technology in cancer research & treatment, 2023-01, Vol.22, p.15330338231154088

2023

Volltextzugriff (PDF)

Postoperative Radiation Therapy in Prostate Cancer: Timing, Duration of Hormonal Treatment and the Use of PSMA PET-CT

International journal of radiation oncology, biology, physics, 2022-06, Vol.113 (2), p.252-253

2022

Volltextzugriff (PDF)

Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer

Frontiers in oncology, 2019-09, Vol.9, p.781

2019

Volltextzugriff (PDF)

Correction to: Metastasectomy for visceral and skeletal oligorecurrent prostate cancer

World journal of urology, 2020-06, Vol.38 (6), p.1589-1589

2020

Volltextzugriff (PDF)

Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news

Ecancermedicalscience, 2020-05, Vol.14, p.1036

2020

Volltextzugriff (PDF)

Re: Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone

European urology, 2019-10, Vol.76 (4), p.537-539

2019

Volltextzugriff (PDF)

Elective nodal radiotherapy in prostate cancer

The lancet oncology, 2021-08, Vol.22 (8), p.e348-e357

2021

Volltextzugriff (PDF)

In Regard to Zelefsky et al

International journal of radiation oncology, biology, physics, 2021-07, Vol.110 (3), p.910-911

2021

Volltextzugriff (PDF)

ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer

European urology, 2023-06, Vol.83 (6), p.508-518

2023

Volltextzugriff (PDF)

Extended field radiotherapy measurements in a single shot using a BaFBr-based OSL-film

Physics in medicine & biology, 2019-08, Vol.64 (16), p.165007-165007

2019

Volltextzugriff (PDF)

277: Adjuvant EBRT for muscle-invasive bladder cancer: phase 2 trial secondary analysis (NCT02397434)

Radiotherapy and oncology, 2024-05, Vol.194, p.S2308-S2311

2024

Volltextzugriff (PDF)

PD42-08 CAN WE USE IMMUNOHISTOCHEMISTRY AS PREDICTING FACTOR OF SUCCESSFUL TREATMENT WITH INTENSIFIED NEOADJUVANT TREATMENT IN HIGH-RISK PROSTATE CANCER: A SUBANALYSIS OF THE ARNEO TRIAL?

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

Another Step Towards the Acceptance of Metastasis-directed Therapy in Low-volume Metastatic Prostate Cancer

European urology oncology, 2022-08, Vol.5 (4), p.428-429

2022

Volltextzugriff (PDF)

Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer

European urology oncology, 2021-04, Vol.4 (2), p.305-309

2021

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Aktive Filter

PublikationsformBuchkapitel

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer

The Use of Soy Isoflavones in the Treatment of Prostate Cancer: A Focus on the Cellular Effects

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial

Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer

SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?

Defining the optimal template of salvage lymph node dissection for unilateral pelvic nodal recurrence of prostate cancer following radical prostatectomy

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial

Metastasectomy for visceral and skeletal oligorecurrent prostate cancer

Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT: impact of postoperative treatments

Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy

Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study

Postoperative Radiation Therapy in Prostate Cancer: Timing, Duration of Hormonal Treatment and the Use of PSMA PET-CT

Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer

Correction to: Metastasectomy for visceral and skeletal oligorecurrent prostate cancer

Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news

Re: Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone

Elective nodal radiotherapy in prostate cancer

In Regard to Zelefsky et al

ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer

Extended field radiotherapy measurements in a single shot using a BaFBr-based OSL-film

277: Adjuvant EBRT for muscle-invasive bladder cancer: phase 2 trial secondary analysis (NCT02397434)

PD42-08 CAN WE USE IMMUNOHISTOCHEMISTRY AS PREDICTING FACTOR OF SUCCESSFUL TREATMENT WITH INTENSIFIED NEOADJUVANT TREATMENT IN HIGH-RISK PROSTATE CANCER: A SUBANALYSIS OF THE ARNEO TRIAL?

PD61-05 ONCOLOGICAL OUTCOMES OF NEOADJUVANT DEGARELIX WITH APALUTAMIDE (ARNEO TRIAL) VERSUS STANDARD OF CARE PRIOR TO RADICAL PROSTATECTOMY FOR HIGH-RISK PROSTATE CANCER: A PROPENSITY SCORE MATCHED ANALYSIS

Another Step Towards the Acceptance of Metastasis-directed Therapy in Low-volume Metastatic Prostate Cancer

Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer

Aktive Filter

Suchergebnisse filtern